Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 67% of modeled bridge. Risk-adjusted uplift: $6.4M (vs $9.6M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $3.6M | $3.6M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $3.5M | $100K | $3.6M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $560K | $1.7M | $2.2M | $7.0M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $117K | $117K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 37.7% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $912K | $1.8M | $2.7M | $3.6M | $3.6M | $3.6M | $3.6M |
| Denial Rate Reduction | $0 | $903K | $1.8M | $2.7M | $3.6M | $3.6M | $3.6M | $3.6M |
| A/R Days Reduction | $0 | $740K | $1.5M | $2.2M | $2.2M | $2.2M | $2.2M | $2.2M |
| Clean Claim Rate | $0 | $58K | $117K | $117K | $117K | $117K | $117K | $117K |
| Cumulative | $0 | $2.6M | $5.2M | $7.8M | $9.6M | $9.6M | $9.6M | $9.6M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $9.6M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 56% / 9.3x | 61% / 10.7x | 65% / 12.1x | 67% / 12.8x | 68% / 13.5x |
| 9.0x | 51% / 7.9x | 56% / 9.2x | 60% / 10.4x | 62% / 11.0x | 63% / 11.7x |
| 10.0x | 47% / 6.8x | 51% / 7.9x | 55% / 9.1x | 57% / 9.6x | 59% / 10.2x |
| 11.0x | 43% / 5.9x | 47% / 6.9x | 51% / 7.9x | 53% / 8.4x | 55% / 8.9x |
| 12.0x | 39% / 5.1x | 43% / 6.1x | 48% / 7.0x | 50% / 7.5x | 51% / 7.9x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 17% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 5.4x, adding 3.0 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $17.1M | — | $17.1M | 9.4% |
| Year 1 | $17.6M | +$6.4M | $24.0M | 13.2% |
| Year 2 | $18.1M | +$9.6M | $27.7M | 15.2% |
| Year 3 | $18.7M | +$9.6M | $28.3M | 15.5% |
| Year 4 | $19.2M | +$9.6M | $28.8M | 15.8% |
| Year 5 | $19.8M | +$9.6M | $29.4M | 16.1% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $1.8M | $2.7M | $3.6M | $4.4M |
| Denial Rate Reductio | $1.8M | $2.7M | $3.6M | $4.3M |
| A/R Days Reduction | $1.1M | $1.7M | $2.2M | $2.7M |
| Clean Claim Rate | $58K | $88K | $117K | $140K |
| Total | $4.8M | $7.2M | $9.6M | $11.5M |
Peer Context — Where This Hospital Sits
Key metrics vs 18 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 9.4% | -8.5% | 3.4% | 12.2% | P59 |
| Net-to-Gross | 24.2% | 25.5% | 33.8% | 37.7% | P18 |
| Occupancy | 48.6% | 49.9% | 73.3% | 84.2% | P22 |
| Rev/Bed | $1.4M | $490K | $1.1M | $1.5M | P65 |
| Exp/Bed | $1.3M | $441K | $945K | $1.8M | P61 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.